These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25423921)

  • 1. [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].
    Komaba H
    Clin Calcium; 2014 Dec; 24(12):1771-8. PubMed ID: 25423921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteo-renal regulation of systemic phosphate metabolism.
    Razzaque MS
    IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Klotho/FGF23 Axis in CKD.
    Tsuchiya K; Nagano N; Nitta K
    Contrib Nephrol; 2015; 185():56-65. PubMed ID: 26023015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
    Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New Developments in CKD-MBD. Why is phosphate overload harmful?].
    Kuroo M
    Clin Calcium; 2014 Dec; 24(12):1785-92. PubMed ID: 25423923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
    Komaba H
    Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD].
    Ando R
    Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
    J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [FGF23 in CKD-MBD].
    Fukumoto S
    Nihon Jinzo Gakkai Shi; 2014; 56(8):1210-7. PubMed ID: 25551981
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of a quantitative systems pharmacology model of chronic kidney disease: metabolic bone disorder.
    Gaweda AE; McBride DE; Lederer ED; Brier ME
    Am J Physiol Renal Physiol; 2021 Feb; 320(2):F203-F211. PubMed ID: 33308018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
    Iwashita Y; Iwashita Y; Ito T; Shigematsu T
    Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New Developments in CKD-MBD. Molecular mechanisms of intestinal and renal phosphate transport].
    Segawa H; Ikuta K; Miyamoto K
    Clin Calcium; 2014 Dec; 24(12):1793-9. PubMed ID: 25423924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
    Evenepoel P; Rodriguez M; Ketteler M
    Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk between kidney and bone: insights from CKD-MBD.
    Suzuki K; Soeda K; Komaba H
    J Bone Miner Metab; 2024 Jul; 42(4):463-469. PubMed ID: 39060498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-renal-Related Mechanisms of FGF23 Pathophysiology.
    Hanudel MR; Laster M; Salusky IB
    Curr Osteoporos Rep; 2018 Dec; 16(6):724-729. PubMed ID: 30353318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.